Kbc Group Nv Viking Therapeutics, Inc. Transaction History
Kbc Group Nv
- $36.3 Billion
- Q4 2024
A detailed history of Kbc Group Nv transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 4,254 shares of VKTX stock, worth $118,346. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,254
Previous 2,997
41.94%
Holding current value
$118,346
Previous $190,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding VKTX
# of Institutions
467Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$283 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$168 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$137 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$72.2 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$60 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.13B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...